沙利多米德可以有效地预防IgG4相关疾病的复发超过其副作用:一个多中心,随机,双盲,安慰剂控制的多中心,随机,双盲研究
Yu Chen1, Cong Ye1, Pingting Yang2
1Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Annals of the rheumatic diseases
|February 16, 2025
概括
与安慰剂相比,thalidomide显著降低了IgG4相关疾病 (IgG4-RD) 患者的复发率. 这项研究表明,thalidomide是预防IgG4-RD复发的安全有效选择,可能允许减少葡萄糖皮质激素的使用.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 免疫球蛋白G4相关疾病 (IgG4-RD) 是一种慢性疾病,其特征是纤维化和炎症.
- 在IgG4-RD中复发很常见,需要有效的长期管理策略.
- 目前的治疗通常涉及长期使用葡萄糖皮质激素 (GC),这与严重的副作用有关.
研究的目的:
- 评估thalidomide在预防IgG4-RD患者疾病复发中的疗效.
- 评估与thalidomide治疗一起减少葡萄糖皮质类药物 (GC) 使用的潜力.
- 为了确定这种患者群体中thalidomide的安全性和风险/益处比.
主要方法:
- 进行了一项多中心,随机,双盲,安慰剂控制的试验.
- 具有活性IgG4-RD的合格患者随机分配,接受GCs加thalidomide或GCs加安慰剂.
- 主要终点是12个月后疾病复发率;次要终点包括缓解率和不良事件.
主要成果:
- thalidomide显著降低了12个月复发率,从安慰剂组的67.8%降至thalidomide组的13.8%.
- 与安慰剂组相比,thalidomide组 (75.8%) 的缓解率更高 (32.1%).
- 不良事件主要是轻微的,中度AEs的危害数 (NNH) 为8,表明有利的风险/益处概况.
结论:
- 塔利多米德在预防IgG4-RD复发方面表现出显著的有效性.
- thalidomide在复发预防中的好处似乎超过了它的副作用.
- 塔利多米德代表了一个潜在的安全治疗选择,用于预防IgG4-RD的类固醇节约性复发.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95
Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118


